Biogen/BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Ticker
BIIB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
7,570
Website
www.biogen.com
Biogen Metrics
BasicAdvanced
$33B
Market cap
28.59
P/E ratio
$8.00
EPS
-0.02
Beta
-
Dividend rate
Price and volume
Market cap
$33B
Beta
-0.02
Financial strength
Current ratio
2.096
Quick ratio
0.954
Long term debt to equity
44.019
Total debt to equity
45.662
Interest coverage (TTM)
6.29%
Management effectiveness
Return on assets (TTM)
4.86%
Return on equity (TTM)
8.05%
Valuation
Price to earnings (TTM)
28.59
Price to revenue (TTM)
3.43
Price to book
2.18
Price to tangible book (TTM)
47.4
Price to free cash flow (TTM)
25.81
Growth
Revenue change (TTM)
-4.37%
Earnings per share change (TTM)
-62.83%
3-year revenue growth
-8.48%
3-year earnings per share growth
-25.42%
What the Analysts think about Biogen
Analyst Ratings
Majority rating from 36 analysts.
Biogen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.3B
-4.01%
Net income
$393M
57.55%
Profit margin
17.17%
64.15%
Biogen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$4.02
$4.36
$3.30
$3.67
-
Expected
$3.77
$3.97
$3.18
$3.45
$4.00
Surprise
6.75%
9.74%
3.66%
6.41%
-
Biogen News
AllArticlesVideos
Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
Accesswire·2 hours ago
UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!
Accesswire·3 hours ago
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Accesswire·8 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $33B as of July 03, 2024.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 28.59 as of July 03, 2024.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of July 03, 2024.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.
Buy or sell Biogen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.